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Abstract
Overcoming the emergence of acquired resistance to clinically approved epidermal growth factor receptor (EGFR)
inhibitors is a major challenge in the treatment of advanced non–small cell lung cancer (NSCLC). The aim of this study
was to investigate the effects of a series of novel compounds affecting viability of NSCLC NCI-H1975 cells (carrying
the EGFR T790Mmutation). The inhibition of the autophosphorylation of EGFR occurred at nanomolar concentrations
and both UPR1282 and UPR1268 caused a significant induction of apoptosis. Targeting of EGFR and downstream
pathways was confirmed by a peptide substrate array, which highlighted the inhibition of other kinases involved in
NSCLC cell aggressive behavior. Accordingly, the drugs inhibitedmigration (about 30% vs. control), which could be, in
part, explained also by the increase of E-cadherin expression. Additionally, we observed a contraction of the volume of
H1975 spheroids, associated with the reduction of the cancer stem–like cell hallmark CD133. The activity of UPR1282
was retained in H1975 xenograft models where it determined tumor shrinkage (P < .05) and resulted well tolerated
compared to canertinib. Of note, the kinase activity profile of UPR1282 on xenograft tumor tissues showed over-
lapping results with respect to the activity in H1975 cells, unraveling the inhibition of kinases involved in pivotal pro-
liferation and invasive signaling pathways. In conclusion, UPR1282 and UPR1268 are effective against various
processes involved in malignancy transformation and progression and may be promising compounds for the future
treatment of gefitinib-resistant NSCLCs.
Neoplasia (2013) 15, 61–72
Abbreviations: CSCs, cancer stem cells; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; FAK, focal adhesion
kinase; NSCLC, non–small cell lung cancer; PCR, polymerase chain reaction; PDAC, pancreatic ductal adenocarcinoma; TKI, tyrosine kinase inhibitor
Address all correspondence to: Prof. Godefridus J. Peters, Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam,
The Netherlands. E-mail: gj.peters@vumc.nl or Dott. Andrea Ardizzoni, Division of Medical Oncology, University Hospital of Parma, V.le Gramsci 14, 43126 Parma, Italy.
E-mail: aardizzoni@ao.pr.it
1This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan grant IG 8856 (A.A.), the Netherlands Organization for Scientific Research (NWO,
Veni grant; E. Giovannetti), AIRC-Marie Curie (International Fellowship; E. Giovannetti, and FIRC grant (Fellowship for abroad; E. Galvani).
2This article refers to supplementary material, which is designated by Figure W1 and is available online at www.neoplasia.com.
3These authors contributed equally to this study.
Revised 31 October 2012; Accepted 12 November 2012
Copyright © 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00
DOI 10.1593/neo.121434
www.neoplasia.com
Volume 15 Number 1 January 2013 pp. 61–72 61
Introduction
Non–small cell lung cancer (NSCLC) represents the majority of
human epithelial cancers [1]. About 10% of NSCLCs is marked by
functional activation of crucial “driver” oncoproteins with a pivotal
dependency on growth factors and their receptors [2]. The epidermal
growth factor receptor (EGFR) is a member of the ErbB family of
receptor tyrosine kinases. These receptors are commonly expressed
in different tissues of epithelial, mesenchymal, and neural origins
and their pivotal role in normal individual development has been
largely investigated. The involvement of EGFR in the regulation of
important tumorigenic processes, such as proliferation, apoptosis,
angiogenesis, and invasion, has also been demonstrated for different
tumor types [3]. Furthermore, activated ErbB receptors stimulate sev-
eral intracellular signaling pathways including the phosphatidylinositol
3-kinase/Akt/mammalian target of rapamycin and the Ras/Raf/mitogen-
activated protein kinase pathways that have been demonstrated to play
a key role in the control of numerous fundamental cellular processes.
Along with its ligands (e.g., EGF, transforming growth factor–α,
neuregulins), EGFR is often overexpressed and negatively correlated
with prognosis in various tumor types, including NSCLC. In partic-
ular, the EGFR overexpression has been observed in 40% to 80% of
NSCLC cases and multiple mutations of such receptor have been
described and correlated with malignancy “oncogene addiction” [3].
Taken together, these findings identified EGFR as an ideal target for
cancer therapy [4]. Small-molecule EGFR tyrosine kinase inhibitors
(TKIs), such as gefitinib and erlotinib, have been approved as first-line
treatment in selected NSCLC patients, as well as second/third-line
treatment or maintenance therapy in unselected patients [3]. The clin-
ical response to TKIs is correlated with activating EGFR mutations,
predominantly the common in-frame deletions of exon 19 (delE746-
A750) and the missense point mutation L858R. These aberrations are
currently used as biomarkers to select patients more likely to benefit
from EGFR TKIs as first-line treatment [5]. Unfortunately, after a
progression-free period of about 10 months, most of the patients
responsive to EGFR TKIs inevitably relapse. The acquired resistance
to first-generation EGFR TKIs can be caused by multiple mechanisms,
including the secondary EGFR point mutation T790M that accounts
for ∼50% of the cases [6,7]. The amplification of the receptor for the
hepatocyte growth factor (c-Met) was also described as important
mechanism of acquired resistance to gefitinib or erlotinib being ob-
served in 20% of the cases [8]. The coexistence of the T790M muta-
tion with c-Met amplification was rarely described [9].
A covalent interaction between EGFR TKIs with a cysteine residue
located at the entrance of the EGFR adenosine triphosphate–binding
cleft (Cys797) was described as a possible mechanism to bypass the
T790M-related resistance to gefitinib. Several second-generation irre-
versible inhibitors have been developed [10–13], and many com-
pounds, such as canertinib [14], afatinib [15], neratinib [16], and
dacomitinib [17], progressed to clinical investigation, with mixed re-
sults. Therefore, acquired resistance against first-line EGFR inhibitors
so far remains one of the major challenges for NSCLC treatment and
the identification of new molecules targeting EGFR T790M mutants
is warranted.
Furthermore, other factors might lay the foundation of drug resis-
tance and novel compounds should be evaluated for their abilities to
overcome also these emerging mechanisms. Recent studies reported
the epithelial-to-mesenchymal transition (EMT) as a pivotal mecha-
nism involved in the resistance of cancer cells against conventional
therapeutics [18,19]. The EMT process results from a number of
dramatic cellular and molecular changes, including dissolution of
adherent junctions, reorganization of the cytoskeleton, loss of cell
polarity, induction of pro-mesenchymal gene expression, and migra-
tion through basement membranes and tissues. Several studies re-
ported the reduction of the expression of the epithelial cell junction
protein E-cadherin as key biomarker of EMT in the development of
resistance to EGFR inhibition in lung cancer [20]. Importantly, the
EMT is also involved in the acquisition of tumor stem–like cell pheno-
type characterized by high potential of self-renewal in vitro and tumor-
igenicity in vivo [21].
We recently developed a new series of irreversible EGFR inhibitors
containing a 3-aminopropanamide fragment. The cytotoxicity of these
compounds was previously tested in vitro in NSCLC H1975 cells [22].
Importantly, these molecules inhibited cell growth at considerably
lower concentrations than gefitinib, showing irreversible inhibition of
EGFR autophosphorylation, in spite of the lack of a cysteine-trapping
warhead [22]. These compounds, while chemically stable in the extra-
cellular environment, proved to be able to release an acrylamide de-
rivative by retro-Michael degradation of the 3-aminopropanamide
fragment in the intracellular environment. In principle, replacing the
reactive acrylamide group of typical second-generation EGFR inhibi-
tors by a chemically stable and basic aminopropanamide should confer
both pharmaceutical (increased stability, water solubility, and bioavail-
ability) and therapeutic (lower propensity to give nonspecific adducts
with biological tissues) advantages. However, the ability of these pro-
covalent inhibitors to exert antiproliferative activity on tumor cells can
depend on the specific intracellular environment and must therefore be
thoroughly examined. In particular, we investigated the activity of the
4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolino derivative UPR1282
and the 4-anilinoquinoline-3-carbonitrile derivative UPR1268 (Figure 1A)
in both in vitro and in vivo models derived from the established gefitinib-
resistant NSCLC H1975 cell line, which harbors the EGFR T790M
mutation. Other pancreatic and lung cancer cell lines were included in
this investigation to compare and understand their effects in diseases
where EGFR inhibitors have demonstrated to be active.
Materials and Methods
Drugs and Chemicals
The synthesis of UPR1282 and UPR1268 has previously been
described by Carmi et al. [22]. Gefitinib was a generous gift from
AstraZeneca (Macclesfield, United Kingdom). The drugs were dis-
solved inDMSO at the stock concentration of 10mM and then diluted
for the experiments in culture medium before use. RPMI medium,
FBS, penicillin (50 IU/ml), and streptomycin (50 μg/ml) were from
Gibco (Gaithersburg, MD). All other chemicals were purchased from
Sigma-Aldrich (Zwijndrecht, The Netherlands).
Cell Culture
The human NSCLC cell lines NCI-H1975 (H1975), Calu-1, and
A549 and the pancreatic ductal adenocarcinoma (PDAC) cell lines
PANC-1 and MIA PaCa-2 were purchased from ATCC (Manassas,
VA) and cultured as recommended. Cells were maintained as mono-
layers in RPMI 1640 (containing 2 mM L-glutamine) supplemented
with 10% heat-inactivated FBS and 1% streptomycin and penicillin
in a 37°C water-saturated atmosphere of 5% CO2 in air in 75-cm
2
tissue culture flasks (Costar, Cambridge, MA). The cell lines were
tested for their authentication by polymerase chain reaction (PCR)
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profiling using short tandem repeats, which was performed by Base-
Clear (Leiden, The Netherlands) in August 2011.
Cell Growth Inhibition
Cell growth inhibition was assessed by sulforhodamine B assay ac-
cording to the National Cancer Institute (NCI) protocol with slight
modifications [23]. The pure compounds were initially dissolved in
DMSO and tested in triplicates in the range of 0.01 to 20 μM. The
treatment was started on day 1 after plating, and cells were exposed to
drugs for 72 hours. The control wells were exposed to 0.1% DMSO.
After 72-hour treatment, 25 μl of ice-cold 50% (wt/vol) trichloro-
acetic acid were added to each well for 60 minutes at 4°C. Then,
the sulforhodamine B assay was performed, as described previously
[24]. The optical density (OD) of each well was measured at 540 nm
by TiterTek Multiskan MCC/340 (Flow Laboratories, Inc, Rockville,
MD) 96-well plate reader. Values were corrected for background OD
from wells containing medium only supplemented with 0.1% DMSO.
The inhibition of cell viability was calculated with respect to control
DMSO-treated cells based on the difference in OD at the beginning
(day 0) and after 72 hours of treatment (day 3), according to the
NCI protocol [23]. The 50% growth inhibitory concentration (IC50)
was expressed as the concentration inhibiting 50% of the growth of
drug-treated cells relative to the DMSO-only–treated ones and calcu-
lated by nonlinear least squares curve fitting (GraphPad Prism, Intuitive
Software for Science, San Diego, CA). Microscopic images of H1975
cells exposed to 0.1% DMSO or UPR1282 and UPR1268 at their
IC50s were taken immediately before (time zero) and after 72 hours
of treatment by Leica DFC345 FX microscope (Leica Microsystems
GmbH, Wetzlar, Germany; Figure W1).
Analysis of Apoptosis with Annexin V Staining and
Mitochondrial Membrane Potential
For the Annexin V staining, H1975 cells were plated at a density
of 2 × 105 cells/well in six-well plates. After 24 hours, 1 μM gefitinib
or UPR1282 and UPR1268 at their respective IC50s were added and
cells were then incubated for 24 hours. DMSO (0.1%) was added to
the control wells. Cells were then trypsinized, harvested, transferred to
test tubes (12 × 75 mm), and centrifuged at 1200 rpm for 10 minutes.
Figure 1. Molecular structure and apoptosis induction of EGFR TKIs in H1975 cells. (A) Molecular structure of gefitinib, UPR1282, and
UPR1268. (B) Annexin V staining: 2 × 105 H1975 cells per well were treated for 24 hours with 0.1% DMSO, 1 μM gefitinib, or UPR1282/
UPR1268 at their respective IC50s. Cells were then stained with Annexin V–FITC and PI, and samples were analyzed by flow cytometry
using excitation/emission wavelengths of 488/525 and 488/675 nm for Annexin V and PI, respectively. (C) Mitochondrial membrane
potential: 2 × 105 H1975 cells per well were treated for 24 hours with 0.1% DMSO, 1 μM gefitinib, or UPR1282/UPR1268 at their
respective IC50s and then incubated with 40 nM DiOC6. The samples were analyzed with the flow cytometer, and living cells were
defined by size (FSC) and granularity (SSC).
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The pellets were resuspended in 100 μl of ice-cold binding buffer
(0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, and 25 μM CaCl2).
Annexin staining was performed according to the manufacturer’s
protocol (Annexin V–Fluorescein Isothiocyanate (FITC) Apoptosis
Detection Kit I; Becton Dickinson, San Jose, CA), with minor mod-
ifications as previously described [25]. Cells were stained with both
5 μl of Annexin V–FITC and 5 μl of propidium iodide (PI) and in-
cubated for 15 minutes at room temperature in the dark before
adding 400 μl of binding buffer to each tube. Samples were then
analyzed by flow cytometry in FACSCalibur Flow Cytometer (Becton
Dickinson) and the results were processed using FACSDiva 6.0
software (Becton Dickinson). A total of 10,000 events were collected
using excitation/emission wavelengths of 488/525 and 488/675 nm
for Annexin V and PI, respectively.
For the analysis of the mitochondrial membrane potential, H1975
cells treated as described above were harvested and transferred to flow
cytometer’s tubes and incubated in phosphate-buffered saline (PBS)
supplemented with 40 nM DiOC6 (Sigma) for 20 minutes at 37°C
in the dark. Then, cells were washed with PBS and the samples were
analyzed with the FACSCalibur Flow Cytometer and the FACSDiva
6.0 software. A total of 10,000 events were acquired and living cells were
defined by size [forward scatter (FSC)] and granularity [side scatter (SSC)].
Genetic Characterization of Cancer Cells
DNA was isolated from 106 cells per cell line, using the MiniDNA
Kit (Qiagen, Hilden, Germany). DNA yields and purity were checked
at 260 to 280 nm with NanoDrop 1000 Detector (NanoDrop Tech-
nologies, Wilmington, DE). Nested PCR to amplify EGFR (exons
18–21) and K-Ras (exons 1–2) and sequencing of PCR products on
an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA)
were performed as described previously [24]. The AKT1-SNP4 G/A
(dbSNP-ID:rs1130233) polymorphism was studied using a Taqman
probe–based assay with specific primers and probes obtained from Ap-
plied Biosystems (C_7489835_10). PCRs were performed using 20 ng
of DNA diluted in 5.94 μl of DNAse-RNAse–free water, with 6.25 μl
of TaqMan Universal PCRMaster Mix and 0.31 μl of the mix, includ-
ing the primers and probes, in a total volume of 12.5 μl. After thermal
cycling, the 7500HT instrument determined the allelic content of each
sample in the plate by reading the generated fluorescence, using the
SDS 2.0 software.
Quantitative Real-Time Reverse Transcription–PCR
Total RNA was isolated using the TRI Reagent LS (Invitrogen,
Carlsbad, CA). One microgram of RNA was retro-transcribed using
the DyNAmo cDNA Synthesis Kit (Thermo Scientific, Vantaa, Finland),
according to the manufacturer’s instructions. Primers and probes
to specifically amplify CD133 and E-cadherin were obtained from
Applied Biosystems Assay-on-Demand Gene expression products
(Hs00901885_m1, Hs01023894_m1). The quantitative real-time
PCR was performed in a 25-μl reaction volume containing TaqMan
Universal Master Mix (Applied Biosystems). All reactions were per-
formed in triplicate using the ABI Prism 7500 sequence detection sys-
tem instrument (Applied Biosystems). Samples were amplified using
the following thermal profile: 50°C for 2 minutes, 95°C for 10minutes,
40 cycles of denaturation at 95°C for 15 seconds followed by annealing
and extension at 60°C for 1 minute. A validation experiment was per-
formed to demonstrate that the efficiencies of the targets (E-cadherin
and CD133) and reference (β-actin) gene amplifications were approx-
imately equal, using a standard curve method with several dilutions of
the cDNA sample from untreated control H1975 cells. An ideal slope
should be −3.32; the values of the slopes of cDNA calibrator relative to
threshold cycle (CT) for the target genes revealed PCR efficiencies above
95%. Amplifications were normalized to β-actin (TaqMan β-Actin
Detection Reagents, Part No. 401846). The fold change was calculated
by the ΔΔCT method and results were plotted as 2
−ΔΔCT.
Western Blot
After 1 hour of exposure to 0.1% DMSO or different concentra-
tions of gefitinib (0.01 to 10 μM) and UPR1282 and UPR1268 (both
from 0.001 to 10 μM), H1975 cells were stimulated for 5 minutes
with EGF (50 μg/ml) and then lysed by RIPA buffer supplemented
with protease and phosphatase inhibitor cocktails. Procedures for pro-
tein extraction, solubilization, and protein analysis by one-dimensional
polyacrylamide gel electrophoresis (PAGE) are described elsewhere
[26]. Samples of 40 to 50 μg of proteins were resolved by 10% sodium
dodecyl sulfate–PAGE and transferred to polyvinylidene difluoride (PVDF)
membranes. The following antibodies were used (Bioké, Leiden, The
Netherlands): polyclonal anti–phospho-EGFR (Tyr1068) [1:1000 in
1:1 solution of Rockland (Rockland Inc, Philadelphia, PA) with PBS
supplemented with 0.05% Tween 20], monoclonal anti-EGFR
(1:1000), polyclonal anti–phospho-Akt (Ser473; 1:1000), monoclonal
anti-Akt (1:1000), polyclonal anti–phospho-p44/42 (Thr202/Tyr204;
1:1000), and monoclonal anti-p44/42 (1:1000). As secondary anti-
bodies, goat anti-mouse InfraRedDye (1:10,000, 800CW; #926-32210
and 680CW; #926-32220; Westburg, Leusden, The Netherlands) or
goat anti-rabbit InfraRedDye (1:10,000, 800CW; #926-32211 and
680CW; #926-32221) were used. As a loading control, expression of
β-actin was determined using an antibody against β-actin in stripped
membranes (1:10,000; Millipore Bioscience Research Agents, Temecula,
CA). Fluorescent proteins were detected by an Odyssey Infrared Imager
(LI-COR Biosciences, Lincoln, NE), at 84-μm resolution, 0-mm offset,
using high-quality settings.
Peptide Substrate Array
To evaluate modulation of kinase activity by gefitinib, canertinib,
and UPR1282 in H1975 cells and tissues from xenograft models, we
profiled lysates from the cells and the tumors by using a kinase peptide
substrate array (PamChip; PamGene International, ’s-Hertogenbosch,
The Netherlands) as previously described [27]. This array contains 144
peptides consisting of 15 amino acids including a tyrosine, usually in
the middle of the peptide. The 13 COOH-terminal amino acids of
each peptide correspond to known or putative phosphorylation sites in
a variety of human proteins. The samples were lysed for 20 minutes at
4°C byM-PER containing phosphatase and protease inhibitors (Thermo
Scientific, Rockford, IL). Lysates were centrifuged for 15 minutes at
10,000g; the supernatant was collected and stored at −80°C. Forty
microliters of control sample mix for the kinase activity array was sub-
sequently prepared by using reaction buffer containing 1× ABL buffer
(Westburg), 100 μM adenosine triphosphate (Sigma-Aldrich),
fluorescein-labeled antibody PY20 (Exalpha, Maynard, MA), 5 μg of
(lysate) protein, and DMSO. Kinase inhibition was measured by the
addition of 25 μM gefitinib, 25 μM canertinib, or 25 μM UPR1282
(final drug concentrations; DMSO concentration in all samples, 2.5%).
After blocking the arrays with 2% BSA and subsequent loading of
the sample mix onto the arrays, incubation (at 30°C) was started for
60 cycles using a PamStation 12 instrument. Repeated fluorescent
imaging of each array was performed with a 12-bit charge-coupled device
(CCD) camera, monitoring fluorescence intensities in real time. Spot
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intensity at each time point was quantified (and corrected for local
background), and the resulting time-resolved curves were fit to calculate
the initial phosphorylation rate (V ini) using specific kinetic algorithms
and appropriate statistical methods, by Bionavigator software version 5.1
(PamGene International).
In Vitro Migration Assay (Wound-Healing Assay)
Migration was evaluated using the LeicaDMI300B migration
station (Leica Microsystems) integrated with the Scratch Assay 6.1
software (Digital Cell Imaging Labs, Keerbergen, Belgium). Thirty
thousand H1975 cells per well were plated onto 96-well plates,
and after 24 hours, artificial wound tracks were created by scraping
with a specific scratcher within the confluent monolayers. After re-
moval of the detached cells by gently washing with PBS, the medium
was replaced and the cells were exposed to 0.1% DMSO, 1 μM
gefitinib, or UPR1282 and UPR1268 at their respective IC50s.
The ability of the cells to migrate into the wound area was assessed
by comparing the pixels of the wound tracks in the images taken at
the beginning of the exposure (time zero) with those taken after 4, 6,
8, and 24 hours [28].
Activity on H1975-Derived Tumor Spheres
A subpopulation of lung cancer stem–like cells were isolated by
culturing 1.5 × 104 H1975 cells per well in serum-free insulin-
transferrin-selenium (1:1000; Gibco, Invitrogen) supplemented with
Dulbecco’s modified Eagle’s medium/F12 + GlutaMAX-I (1:1), in
24-well ultralow adherent plates (Corning Incorporated, Corning,
NY), according to the manufacturers’ protocol, as previously described
[28]. The spheroids were generated for 20 to 25 days and then har-
vested for the growth inhibition studies in 96-well plates, as well as for
RNA isolation. After checking their growth and stability, H1975
spheroids were treated with 0.1% DMSO, 1 μM gefitinib, as well
as UPR1282 or UPR1268 at their IC50s. Each well was scanned
at 0, 24, 48, and 72 hours of treatment. The effects of the drugs
were evaluated in term of changes in the volume and in the total
number of spheroids using the inverted phase contrast microscope
LeicaDMI300B integrated with the Universal Grab 6.3 software
(Digital Cell Imaging Labs). The volume of the spheroids (V )
was calculated as volume of spheres having as diameter the average
of the maximum and minimum diameters [D = (Dmax + Dmin)/2;
V = 4/3π(D/2)3] obtained from the images by measurement with
ImageJ software (ImageJ 1.45s; byWayne Rasband, National Institutes
of Health, Bethesda, MD).
Tumor Xenografts
All experiments involving animals were performed in accordance
with Guiding Principles in the Care and Use of Animals (DL116/92).
Twenty-four BALB/c-Nude female mice (Charles River Laboratories,
Calco, Italy) were housed in a protected unit for immunodeficient
animals with 12-hour light/dark cycles and provided with sterilized
food and water ad libitum. At the time of xenograft experiments, mice
were 7 weeks old and weighted about 20 g. Two hundred microliters
of matrigel (BD Biosciences, Franklin Lakes, NJ) and sterile PBS (1:1)
containing 1 × 107 H1975 cells were subcutaneously injected on the
right flank of each mouse (using a 1-ml syringe, needle G25). The
injected cells generated a solid tumor localized in correspondence of
injection site. When tumor volume reached an average size of 150 to
200 mm3, 1 month after injection, animals were randomized into
four groups and treated for 25 days. At the end of the treatment, mice
were killed by cervical dislocation and tumors were collected and
stored at −80°C until used for peptide kinase array or formalin fixed
for hematoxylin-eosin staining or immunohistochemistry.
Treatment and Tumor Measurement
Gefitinib, canertinib, and UPR1282 were orally administered,
5 days/week, at the dosage of 25 mg/kg in 1% Tween 80, while the
animals in the control group received oral gavage of vehicle alone.
Tumor xenografts were measured twice a week and tumor volume
was calculated using the formula: (length × width2)/2. Final data are
expressed as percentage of volume increase: tumor volume/pretreatment
tumor volume × 100.
Sections of formalin-fixed, paraffin-embedded xenograft tumors
were stained with hematoxylin and eosin for initial histopathologic
examination to confirm the presence of NSCLC cells. This is a widely
used, two-stage stain for cells in which hematoxylin is followed by a
counterstain of red eosin so that the nuclei stain a deep blue-black and
the cytoplasm stains pink. This staining allows the detection of focally
multinucleated cells and mitotic figures within the tumors.
Immunohistochemistry
Tumor tissue sections were constructed using tissue biopsies ob-
tained from three mice from the different groups included in recipient
paraffin blocks. Before staining with the monoclonal antibody from
the EGFR pharmDx Kit, the slides were deparaffinized using xylene
and rehydrated in alcohol, as described previously [29]. Negative con-
trols were obtained by replacement of primary antibody with buffer
(1× PBS). EGFR staining results were evaluated using a four-tier
system including the analysis of both the number of positive cells
and the staining intensity. All slides were reviewed by two indepen-
dent observers who also evaluated the amount of tissue loss, back-
ground staining, and overall interpretability before the formal EGFR
reactivity evaluation. Neoplastic cells were always uniformly stained,
and positivity assessment was made by counting at least 2000 tumor
representative cells.
Statistical Analysis
All experiments were performed in triplicate and repeated at least
twice. Data were expressed as mean values ± SD and analyzed using
the two-tailed Student’s t test or analysis of variance followed by the
Bonferroni’s multiple comparison test, using Prism 5.0 (GraphPad
Software). The level of significance was set at P < .05.
Results
Antiproliferative and Cytotoxic Effects
The novel UPR1282 and UPR1268 compounds (Figure 1A) were
evaluated in comparison to the first-generation EGFR TKI gefitinib
for their ability to inhibit the growth and viability of different cell
lines, including the gefitinib-resistant H1975 cell line harboring
the T790M mutation (Table 1). The 4-(3-chloro-4-fluoroanilino)-
7-ethoxyquinazolino derivative UPR1282 was significantly more
active in comparison with gefitinib in the three tested NSCLC cell
lines. In particular, UPR1282 was nine-fold more effective than
gefitinib in inhibiting H1975 proliferation but only two-fold in the
NSCLC cell lines A549 and Calu-1. Because of the approval of the
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EGFR TKI erlotinib in combination with gemcitabine [30], for the
treatment of advanced PDAC, we also evaluated the biological activity
of our compounds in PDAC cells. Our molecules were as active as
gefitinib in inhibiting the proliferation of both PANC-1 and MIA
PaCa-2 cells. Moreover, a 16-fold difference compared to gefitinib
was observed with UPR1268 in H1975 cells. This compound was
also nine- and two-fold more effective than gefitinib in reducing
A549 and Calu-1 cell viability, respectively. Furthermore, in the PDAC
cells MIA PaCa-2, the same compound showed a five- to six-fold in-
crease in potency with respect to the first-generation EGFR TKI. The
inhibition of H1975 cell proliferation was detected also microscopically
after exposure of the cells to UPR1282 and UPR1268 at their IC50s
(Figure W1).
Apoptosis was investigated as potential mechanism of cell death
induced by these compounds using cytofluorometric analysis of
Annexin V staining and mitochondrial membrane potential. One
micromolar gefitinib was chosen as treatment of reference, as it is
the concentration more commonly used in the preclinical setting to
reflect the mean blood concentration reached in NSCLC patients
treated with the inhibitor. In apoptotic cells, the membrane phospho-
lipid phosphatidylserine is translocated from the inner to the outer
leaflet of the plasma membrane, thereby exposing phosphatidylserine
to the external cellular environment. Annexin V labeled with the
FITC fluorescent tag was used with flow cytometry to measure this
event. Moreover, because Annexin V staining precedes the loss of
membrane integrity that accompanies the later stages of cell death
resulting from either apoptotic or necrotic processes, we used the
staining with Annexin V–FITC in conjunction with a live/dead dye
such as PI to allow the identification of early apoptotic cells (PI
negative, Annexin V–FITC positive) from late apoptotic/dead cells
(PI positive, Annexin V–FITC positive). The 24-hour treatment with
the novel molecules increased both events, as illustrated in Figure 1B.
In particular, IC50s of UPR1282 and UPR1268 increased the early
apoptosis from 3.9 to 16.0 and 10.8% and the late apoptosis from
4.4 to 9.6 and 12.2%, respectively. Mitochondrial damage was assessed
biochemically by measuring DiOC6, a cationic dye that is released
when the mitochondrial membrane potential is damaged. As shown
by the representative histograms of cytofluorometric analysis in
Figure 1C , a clear decrease in the binding of DiOC6 was observed in
H1975 cells treated for 24 hours with UPR1282 and UPR1268, as
described above. Conversely, no differences were observed in cells
treated with gefitinib compared to control cells that were exposed to
0.1% DMSO (Figure 1, B and C).
Inhibition of EGFR Autophosphorylation and Downstream
Signaling Pathways
To get further insights into the mechanism of action of the new
compounds compared to gefitinib, we investigated their effect on
Table 1. Human Cancer Cell Line Characteristics and Sensitivity to EGFR TKIs.
Cell Line Histology EGFR Status K-Ras Status AKT1 SNP4 Gefitinib IC50 (μM) UPR1282 IC50 (μM) UPR1268 IC50 (μM)
H1975 (NSCLC) Adenocarcinoma L858R WT GG 11.7 ± 1.3 1.2 ± 0.5* 0.6 ± 0.1*
T790M
A549 (NSCLC) Adenocarcinoma WT Mut (G12S) GA 6.4 ± 0.8 3.4 ± 0.3* 0.7 ± 0.1*
Calu-1 (NSCLC) Squamous cell carcinoma WT Mut (G12C) GG 19.3 ± 1.2 8.6 ± 0.2* 8.0 ± 0.5*
PANC-1 (PDAC) Epithelioid carcinoma WT Mut (G12D) AA 7.6 ± 0.4 7.7 ± 1.1 5.6 ± 0.1*
MIA PaCa-2 (PDAC) Carcinoma WT Mut (G12C) AA 14.1 ± 0.2 11.6 ± 0.3* 2.4 ± 0.1*
Data on determinants of gefitinib sensitivity in NSCLC cell lines have been published by Giovannetti et al. [24]. Mut, mutation; WT, wild type.
*P < .05 with respect to gefitinib treatment.
Figure 2. EGFR and downstream pathway phosphorylation analyses by Western blot; 1 × 106 H1975 cells per well were plated in six-
well plates and, after 24 hours, were exposed for 1 hour to 0.01 to 10 μM gefitinib, 0.001 to 10 μM of both UPR1282 and UPR1268, or
0.1% DMSO (control). Stimulation with EGF (50 μg/ml) for 5 minutes was performed before protein extraction. Samples of 40 to 50 μg of
proteins were resolved by 10% sodium dodecyl sulfate–PAGE and transferred to PVDF membranes. Fluorescent proteins were detected
and analyzed by Odyssey Infrared Imager at 84-μm resolution, 0-mm offset, using high-quality settings. The immunoblot of gefitinib activity
in H1975 cells has been previously published by Carmi et al. [10].
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crucial phosphorylation pathways (Figure 2). A concentration-
dependent inhibition of EGFR autophosphorylation in H1975 cells
was observed after exposure to both UPR1282 and UPR1268, with
IC50 of 0.08 and 0.15 μM, respectively. A complete inhibition of
EGFR phosphorylation was reached by both UPR compounds at the
highest tested concentration (10 μM). In the same experimental con-
ditions, gefitinib only slightly reduced EGFR autophosphorylation at
10 μM. As a consequence of the inhibition of the receptor, both our
novel compounds affected the phosphorylation of the downstream
signaling molecules p-Akt and p-p44/42, whereas gefitinib had a mar-
ginal effect on p-Akt at 10 μM. Furthermore, we investigated alterations
of core signaling pathways after exposure to UPR1282, in compari-
son with gefitinib and canertinib, using a recently established high-
throughput kinase array [27]. In cell lysates, kinase activity profiling
was performed in the absence and presence of 25 μM gefitinib,
canertinib, or UPR1282. Data of V ini in treated cells were compared
to the DMSO-treated ones and a total of 28, 43, and 21 kinases, linked
to many peptide substrates, were identified with a percentage of in-
hibition of more than 66.6%, caused by gefitinib, canertinib, and
UPR1282, including nine common targets (Table 2). Importantly,
EGFR, ErbB2, and ErbB4 inhibition was observed as a consequence
of each treatment.
EMT and Inhibition of Cellular Migration
Accumulating evidence suggests a critical role of EMT in epithelial
cancer progression, invasion, and metastasis. Cell features, including
cell-cell and cell-matrix interactions, are highly affected by EMT, and
loss of intracellular cohesion, together with the disruption of extra-
cellular matrix (ECM) and modifications of the cytoskeleton, has been
related to increased cell motility and invasiveness [31]. The family of
cadherins comprises molecules that are involved in cell-cell adhesion,
and their deregulation may result in EMT and cell motility. Recent
studies demonstrated the correlations between cell-cell contact and
cytoplasmic signaling pathway activation or inhibition [32]. Wnt sig-
naling has emerged as critical pathway in lung tumorigenesis through
the β-catenin–mediated transcription of zinc-finger proteins such as Slug
and Snail, in which expression is inversely correlated with E-cadherin
transcription [33]. Destruction of E-cadherin by receptor tyrosine
kinases and Ras pathway was demonstrated to cause release of β-catenin
from disassembled junctions between epithelial cells and promote cell
transformation [34]. Thus, E-cadherin was first investigated by reverse
transcription (RT)–PCR as molecule related to cellular migration.
Whereas gefitinib did not affect the level of E-cadherin mRNA in
H1975 cells, the exposure to the novel irreversible inhibitors signifi-
cantly increased its gene expression when compared to DMSO-treated
cells (Figure 3A). Furthermore, to explore whether UPR1282 and
UPR1268 affect cell migration, a scratch motility assay was performed
in H1975 cells. Both molecules significantly reduced cell migration in
comparison to the control, whereas gefitinib did not result in any effect
(Figure 3, B and C).
Volume Reduction of H1975-Derived Tumor Spheres
Results from earlier studies illustrated that the sensitivity of two-
dimensional monolayer cell cultures to anticancer drugs is different
from that obtained in three-dimensional culture models [35]. Further-
more, the cancer stem cell (CSC) theory prompted to the reexamination
of established views of tumor initiation, progression, and therapeutic
resistance [36]. Recently, the use of serum-free medium has been re-
ported to select cell populations harboring CSC-like characteristics,
including self-renewal and differentiation into heterogeneous lineages
of cancer cells [37]. This experimental approach represents the best
strategy so far to obtain the expansion of the tumorigenic cell sub-
population. Furthermore, recent studies unraveled the importance
of CSC CD133-positive cells in tumorigenicity and chemoresistance
of lung cancer [38]. Thus, to determine whether three-dimensional
systems, enriched with CSC-like properties, could be affected by our
compounds, we developed tumor spheres from H1975 cells that, after
Table 2. Kinase Activity Profiles of Gefitinib, Canertinib, and UPR1282 in H1975 Cells.
Peptides Gef Can UPR
ANXA1_14_26 X
ANXA2_17_29 X X
B3AT_39_51 X
PGFRB_1014_1028 X
CALM_95_107 X X X
CBL_693_705 X
CD3Z_116_128 X
CD3Z_146_158 X
CDK2_8_20 X
DCX_109_121 X X X
EGFR_1190_1202 X X
EGFR_862_874 X
EPHA4_589_601 X X
EPHB1_771_783 X
EPHB4_583_595 X X
EPOR_361_373 X X
ERBB2_870_882 X
ERBB4_1181_1193 X
ERBB4_1277_1289 X
FAK1_569_581 X
FAK2_572_584 X
FES_706_718 X
FGFR3_641_653 X X
JAK1_1015_1027 X
JAK2_563_577 X
K2C6B_53_65 X X X
K2C8_425_437 X X
KSYK_518_530 X
LCK_387_399 X
MK01_180_192 X X
MK10_216_228 X X X
MK14_173_185 X
NTRK1_489_501 X X X
NTRK2_509_521 X X X
ODPAT_291_303 X X X
PP2AB_297_309 X
PECA1_706_718 X
PERI_458_470 X X
PLCG1_1246_1258 X
PLCG1_776_788 X
PRGR_545_557 X
PRGR_786_798 X
RASA1_453_465 X X X
RBL2_99_111 X X
RON_1346_1358 X X
RON_1353_1365 X
STAT1_694_706 X X
STAT4_714_726 X X
TNNT1_2_14 X X
TYRO3_679_691 X X
VGFR1_1046_1058 X X
VGFR1_1162_1174 X
VGFR1_1235_1247 X X
VGFR2_1046_1058 X
VGFR2_1052_1064 X X
VGFR2_1168_1180 X X
VGFR2_1207_1219 X X X
VGFR3_1061_1073 X X
Gef, gefitinib; Can, canertinib; UPR, UPR1282; X, percentage of kinase inhibition of more than
66.6% in comparison with untreated H1975 cells. The acronyms refer to peptides/proteins from
http://www.expasy.org/uniprot/.
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20 to 25 days of culture, reached a size of approximately 400 to 500 μm
in diameter (Figure 4A). We evaluated then by RT-PCR the level of
CD133 mRNA as marker of stemness, comparing adherent cells versus
tumor spheres. In agreement with previous studies, a significantly
higher expression of CD133 mRNA was observed in tumor spheres
when compared to adherent cells (Figure 4B).When treated with gefitinib
or the novel TKIs, the total number of H1975 spheroids was not af-
fected. However, the treatment with the novel inhibitors significantly
reduced tumor sphere volume when compared to the time zero of treat-
ment (Figure 4, C and D). In contrast, gefitinib treatment did not af-
fect the growth of these three-dimensional spheroidal systems (data not
shown). Furthermore, the exposure of tumor spheres to UPR1282 and
UPR1268 significantly reduced CD133 gene expression (Figure 4E),
whereas the treatment with gefitinib did not cause any change in
CD133 mRNA when compared to DMSO-only–treated spheroids
(data not shown).
Tumor Shrinkage in H1975 Xenograft Model and Signaling
Pathway Inhibition in Tumor Tissue
To evaluate the potential of our compounds in vivo, we tested the
effects of UPR1282 in comparison with gefitinib and canertinib
(H1975 IC50 = 2.4 μM) in H1975-derived xenografts. When tumors
were well established and reached an average volume of 150 to 200mm3,
the mice were randomized into four treatment groups receiving
gefitinib, canertinib, UPR1282, or vehicle. The treatment with either
canertinib or UPR1282 caused tumor shrinkage, whereas gefitinib did
not affect tumor growth in comparison to the control group
(Figure 5A). Of note, canertinib significantly inhibited tumor growth
after 21 days of treatment. However, this shrinkage was accompanied
by a significant reduction of animal body weight compared to untreated
animals as well as to mice treated with UPR1282 (Figure 5B). Immuno-
histochemistry was then performed on three tumor tissues per group
and EGFR was evaluated as marker to confirm the origin of the tumor
from our human lung cancer cells (Figure 5C ). To evaluate the activity
of our novel drug in tumor tissues, we performed an additional kinase
activity profiling in tissue lysates, in the absence or presence of 25 μM
UPR1282. Data of V ini in treated lysates from H1975 xenograft
specimens, which according to hematoxylin-eosin staining in Figure 5C
contained more than 80% of tumor cells, were compared to data ob-
tained from the treatment of H1975 cell lysate. This array identified
a strong percentage of inhibition (i.e., more than 66.6%) of 17 and
21 kinases in tissue and cell lysates, respectively, including seven
Figure 3. Effects of EGFR TKIs on H1975 cell migration. (A) E-cadherin evaluation by quantitative RT-PCR after exposure of H1975 cells
to 1 μM gefitinib or UPR1282 and UPR1268 to their respective IC50s for 24 hours. (B) Representative images of the wound tracks (created
24 hours after plating 3 × 105 H1975 cells per well) in time with different treatments. The control is represented by cells exposed to 0.1%
DMSO. (C) Comparison of the effect of the different treatments on the percentage of cell migration. After 24 hours since plating, cells
were treated with 0.1% DMSO, 1 μM gefitinib, 1.2 μM UPR1282, or 0.6 μM UPR1268. The wound areas were measured after 0, 4, 6, 8,
and 24 hours of treatment. The percentages of migration are referred to the time zero measurements and represent the averages of four
replicates repeated in three independent experiments.
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common targets (Figure 5D). Importantly, EGFR inhibition by
UPR1282 was confirmed by the peptide substrate array in both tissue
and cells, confirming its powerful activity on this target.
Discussion
The present study demonstrates the activity of novel EGFR irreversible
inhibitors against tumor cells, including in vitro and in vivo models of
EGFR T790M NSCLC. Moreover, we evaluated several molecular
mechanisms underlying the abilities of these novel compounds to effec-
tively antagonize NSCLC aggressive and invasive behavior.
Molecular targeting of EGFR with the first-generation reversible
TKIs gefitinib and erlotinib is now an established therapeutic option
in advanced NSCLC patients who harbor activating mutations of the
receptor [39]. However, the emerging acquired resistance together with
the low survival benefit prompts further studies to improve this thera-
peutic approach. The necessity to overcome the resistance due to the
T790M secondary mutation of EGFR led to the development of several
second-generation irreversible TKIs of this target [3]. We recently syn-
thesized a series of novel 3-aminopropanamide compounds that dem-
onstrated to be active against H1975 NSCLC cells harboring the
EGFR T790Mmutation by irreversible binding to the receptor follow-
ing intracellular activation to a cysteine-trapping chemical species [22].
The present study demonstrates that the two most promising com-
pounds inhibit cell proliferation and induce apoptosis in different
NSCLC cell lines at significantly lower concentration than gefitinib.
Because the EGFR TKI erlotinib has been approved for the treatment
of advanced PDAC in combination with gemcitabine [30], we also
evaluated the new molecules in PANC-1 and MIA PaCa-2 cells. In
these cell lines, both our compounds were as active as gefitinib or even
more active than the first-generation EGFR TKI. However, the very
slight increase in survival obtained with the use of erlotinib [40] and
the recent success of multicombinatorial approaches with conventional
cytotoxic drugs reduce the impact of EGFR TKIs in the treatment of
PDAC [41].
As expected on the basis of their anti-EGFR activity, the main
downstream mediators of the EGFR signal transduction pathways
(p-Akt and p-p44/42) were also affected by our novel compounds.
However, despite EGFR inhibition was already detectable byWestern
blot in the nanomolar range of concentrations, the downstream signal-
ing molecules were slightly inhibited at 1 μM, particularly by UPR1268,
and more clearly at the highest used concentration (10 μM) for both the
inhibitors. Furthermore, using a commercially available 144-peptide
array, we detected other tyrosine kinases affected by UPR1282. The
restricted subset of the peptides spotted on the array, together with
the limited specificity and the use of lysates that cannot reproduce sub-
cellular compartmentalization and protein docking or scaffolding,
represent the main interdiction of this study [42]. However, several
Figure 4. Effects of EGFR TKIs on H1975 grown as spheroids. (A) Composite representative image of an experimental well containing
several spheroids. (B) Comparison of CD133 mRNA by quantitative RT-PCR in H1975 adherent cells versus tumor spheres. The fold
change of CD133 mRNA in spheroids was calculated using the 2−ΔΔCT method relative to adherent cells used as control. (C) Represen-
tative image of diameter measurement in the evaluation of spheroid volume. (D) After 20 to 25 days, H1975 spheroids were treated with
1 μM gefitinib as well as with UPR1282 and UPR1268 at their IC50s. The volume of the spheroids was measured at 24-, 48-, and 72-hour
treatment and normalized to the volume of the spheroids at time zero treatment. (E) CD133 evaluation by quantitative PCR after expo-
sure of tumor spheres to 1 μM gefitinib or to UPR1282 and UPR1268 at their IC50s for 24 hours.
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additional tyrosine kinases that were significantly inhibited by
UPR1282, including the fibroblast growth factor receptor 3, whose
up-regulation has been correlated to radioresistance in squamous cell
carcinoma, were identified [43]. Of note, EphB4 and the focal adhesion
kinase 1 (FAK1), which are both involved in the neoplastic transforma-
tion process, were also inhibited by UPR1282 in H1975 cells [44,45].
Additionally, the treatment of the cell lysates with UPR1282 also in-
hibited c-Met, in which amplification represents the second cause of
acquired resistance to the treatment with EGFR TKIs. In particular,
the activity of the receptor was reduced by around 53% by UPR1282.
Importantly, many kinases, including the previously mentioned, had
relevant (although not always below the 66.6% threshold) levels of
inhibition in both H1975 cell line and xenografts exposed to UPR1282.
These results potentially extend the use of UPR1282 to the treatment
of NSCLCs that harbor mechanisms of resistance different than the
EGFR T790M mutation.
The invasive and metastatic capacity of tumor cells constitute two
pivotal mechanisms of malignant tumor development. The poor prog-
nosis of lung cancer is related to strong metastasis potential, which is
directly correlated with EMT [33]. The transformation of epithelial
cells to motile, invasive, and migratory mesenchymal cells is the major
feature of such process. Cell adhesion and detachment are regulated by
interactions between cell-cell and cell-ECM that coordinate the inva-
sive mechanism [46]. Several classes of proteins participate to invasive
cancer phenotype. Recent studies reported the loss of function of the
cadherin adhesion complex, and in particular E-cadherin, as hallmark
Figure 5. Effects of EGFR TKIs in xenograft models. (A) Effect of treatments with reversible and irreversible TKIs on tumor growth in a
human NSCLC xenograft model. H1975 cells were suspended in a matrigel and sterile PBS (1:1) and implanted subcutaneously (right
flank) on female BALB/c-Nude mice. Tumors were allowed to grow for 1 month, and the treatments started when they reached an
average volume of 150 to 200 mm3. Vehicle, gefitinib, canertinib, or UPR1282 were administered orally 5 days per week, at a dosage
of 25 mg/kg, for all the duration of the study. Data are expressed as percentage of change in tumor volume ± SEM. (B) Effect of the
chronic treatment of mice with vehicle, gefitinib, canertinib, or UPR1282 administered orally 5 days per week, at a dosage of 25 mg/kg
on animal body weight. Data are expressed as percentage of change in tumor volume ± SEM. (C) Representative tumor xenograft
staining with hematoxylin and eosin and immunohistochemistry for EGFR of tissues from xenografts from control and UPR1282-treated
groups. (D) Venn diagram of kinase profiles obtained from cells and tissue lysates treated with 25 μMUPR1282. After loading of the sample
mix onto the arrays, incubation (at 30°C) was started for 60 cycles utilizing a PamStation 12 instrument. Repeated fluorescent imaging of
each array was performed to monitor fluorescence intensities in real time. Spot intensity was quantified and the resulting time-resolved
curveswere fit to calculate the initial phosphorylation rate (V ini) using specific kinetic algorithms and appropriate statisticalmethods. Kinases
that were identified to be inhibited more than 66.6% compared to DMSO-treated lysates of both cells and tissues are plotted in the
Venn diagram.
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of EMT that leads to increased proliferation, invasiveness, and metas-
tasis [47]. Thus, we investigated whether the exposure to UPR1282 or
UPR1268 might affect E-cadherin gene expression. Whereas treatment
with gefitinib did not affect the level of mRNA coding for E-cadherin
inH1975 cells, a significant increase in its gene expression was observed
after exposure to our novel compounds. Furthermore, since recent stud-
ies demonstrated that EGF modifies cell-ECM adhesion [48], we tested
whether our compounds might affect migration of EGFR T790M
H1975 cells. Differently from what was observed after exposure to gefi-
tinib, the novel 3-aminopropanamide compounds significantly reduced
cell migration after few hours of treatment, as detected by the wound-
healing assay. Such reduction in cell motility agrees with previous evi-
dence on FAK inhibition and increased E-cadherin gene expression.
Accumulating evidence suggests that specific subpopulations of
cancer cells within the bulk of tumors undergo different degree of
EMT, and this process has been related with the acquisition of stem
cell–like characteristics. Both EMT and stemness are implicated in the
pathogenesis and chemoresistance of heterogeneous malignant tumors
[21,49]. Treatment strategies for the elimination of cancer, therefore,
need to consider the presence of CSCs. Sphere assay has proven to be
an excellent technique to isolate CSCs and several studies demonstrated
that the three-dimensional aggregates can contain different cell pro-
liferation and metabolic gradients, such as an outer rim of viable and
actively proliferating cells and an inner necrotic region [35]. Thus,
after generating tumor spheres that overexpress the stem/initiating cell
marker CD133, we explored whether our novel EGFR TKIs affected
spheroid growth. Conversely to gefitinib, both the 3-aminopropanamide
derivatives significantly reduced tumor sphere dimensions. Further-
more, we demonstrated that the level of CD133 mRNA was reduced
after exposure to UPR1282 and UPR1268 [37,50].
The evaluation of the activity of UPR1282 was also extended to xeno-
graft models of EGFR T790M NSCLC. The chronic administration of
UPR1282 in athymic mice was well tolerated and produced significant
inhibition of tumor growth, which might result from inhibition of
both EGFR and downstream kinase activities. Of note, whereas tumor
shrinkage induced by canertinib treatment was accompanied by signifi-
cant toxicity, UPR1282 did not induce significant loss of body weight
and toxicity even after a prolonged treatment. This might be, at least in
part, related to the masking of acrylamide warhead that results in reduced
risk of covalent interaction with off-target molecules [22].
In conclusion, our 3-aminopropanamide irreversible EGFR TKIs
seem very promising anticancer agents by attacking different key mech-
anisms involved in the resistance of NSCLC cells to the first-generation
EGFR TKIs gefitinib and erlotinib, including the EMT process. These
data should prompt future trials that will give the ultimate proof of the
utility of these novel anticancer agents for the treatment of lung cancer.
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Figure W1. Cell growth inhibition. Microscopic view of the inhibitory effect of UPR1282 and UPR1268 on H1975 cell proliferation.
Images were taken after 0- and 72-hour treatment with 0.1% DMSO or UPR1282 and UPR1268 at their respective IC50s.
